<DOC>
	<DOCNO>NCT01271075</DOCNO>
	<brief_summary>This double-blind , triple cross-over , placebo-controlled study ass efficacy , mechanism , safety treatment antihistamine bilastine patient cold contact urticaria ( CCU ) . Efficacy primarily assess change critical stimulation time threshold ( CSTT ) critical temperature threshold ( CTT ) treatment different dosage bilastine ( 20 mg , 40 mg , 80 mg ) . Following baseline period 2-4 week , patient randomize either group A group B . In group A give bilastine 20 mg , 40 mg , placebo bilastine 80 mg 7 day follow 14-day washout period time . In group B give bilastine 80 mg , placebo , 40 mg 20 mg 7 day follow 14-day washout period time . CSTT CTT testing perform 6 visit , skin microdialysis assessment mast cell mediator perform V2 , V3 V6 . Visits investigator 's assessment schedule day -14 -28 , day 0 , day 7 , day 28 , day 49 , day 70 . Overall max . 20 subject cold contact urticaria enrol .</brief_summary>
	<brief_title>Bilastine Updosing - Characterization Underlying Mechanisms</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<criteria>Informed consent sign date Reliable method contraception woman childbearing potential well man study 3 month thereafter . A highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , IUDs , sexual abstinence vasectomise partner Outpatients CCU 6 week . Urticaria symptom must comprise wheal itch . Age 18 year . No participation clinical trial 1 month participation study Subjects inmates psychiatric ward , prison , state institution . Existing plan placement institution rule accord ยง 40 passage 1 , number 4 AMG ( Arzneimittelgesetz ) The presence permanent severe disease , especially affect immune system , except urticaria cold urticaria The presence permanent gastrointestinal condition may influence oral therapy ( chronic diarrhoea disease , congenital malformation surgical mutilation gastrointestinal tract ) History presence epilepsy , significant neurological disorder , cerebrovascular attack ischemia History presence myocardial infarction cardiac arrhythmia require drug therapy ECG alteration repolarisation ( QTc prolongation &gt; 450ms ) Blood pressure &gt; 180/100 mmHg and/or heart rate &gt; 100/min . Evidence significant hepatic renal disease ( GOT and/or GPT 3 time upper reference value , serum creatinine 1.5 time upper reference value ) History adverse reaction bilastine know hypersensitivity bilastine ingredient Presence active cancer require chemotherapy radiation therapy Presence alcohol abuse drug addiction Intake oral corticosteroid within 14 day prior screen visit Use depot corticosteroid chronic systemic corticosteroid within 21 day prior screen visit Use systemic immunosupressants/immunomodulators like ciclosporine A , dapsone , methotrexate , mycophenolate , chloroquine , comparable drug within 28 day prior screen visit Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>urticaria</keyword>
	<keyword>bilastine</keyword>
</DOC>